Advertisement

Klotho Ameliorates Cellular Inflammation via Suppression of Cytokine Release and Upregulation of miR-29a in the PBMCs of Diagnosed Alzheimer’s Disease Patients

  • Mohsen SedighiEmail author
  • Tourandokht Baluchnejadmojarad
  • Soudabeh Fallah
  • Nariman Moradi
  • Siamak Afshin-Majdd
  • Mehrdad Roghani
Article
  • 14 Downloads

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized by neural inflammation and oxidative stress. In the current study, the protective effects of klotho and linagliptin treatment on human peripheral blood mononuclear cells (PBMCs) of AD patients and healthy controls (HCs) are assessed through measurement of inflammatory cytokines, signaling proteins, and miRNA expression. Sixteen diagnosed AD patients and sixteen HCs were enrolled in the study. Blood samples were obtained and PBMCs were isolated. PBMCs were treated with klotho at different concentrations (0.5, 1, and 2 nM) and linagliptin (50 μM). The concentration of interleukin-1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), epsilon isoform of protein kinase C (PKCε), phosphorylated cyclic AMP response element binding (pCREB), and Wnt1 were measured by ELISA. The expression of miR-29a and miR-195 was detected by real-time PCR. The results showed that klotho significantly reduced IL-1β, IL-6, and TNF-α levels in both groups of the experiment. Linagliptin also remarkably reduced TNF-α levels in the AD group. Moreover, klotho caused the downregulation of Wnt1 in the PBMCs of both groups and the upregulation of the pCREB in HCs. Meanwhile, klotho induced miR-29a expression in the PBMCs of HCs, while miR-29a expression was induced in the AD group by klotho and linagliptin. The current findings revealed that klotho alleviates inflammation in human PBMCs, probably through the suppression of inflammatory cytokines and the upregulation of miR-29a, and part of its beneficial effect is mediated through appropriate modulation of the Wnt1/pCREB signaling cascade. In addition, linagliptin exerts protective effects by reducing TNF-α and inducing miR-29a expression in PBMCs.

Keywords

Alzheimer’s disease Cytokines Klotho Linagliptin miRNAs 

Notes

Acknowledgments

This study has been adapted from a PhD thesis at Iran University of Medical Sciences (Tehran, Iran).

Funding

This work was financially supported (grant # 95-01-87-27994) by Iran University of Medical Sciences.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that there is no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Iran University of Medical Sciences and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Philos Trans R Soc Lond Ser B Biol Sci 358(1438):1669–1677Google Scholar
  2. Atkin SL, Katsiki N, Banach M, Mikhailidis DP, Pirro M, Sahebkar A (2017) Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: a systematic review and metaanalysis of controlled trials. J Diabetes Complicat 31(9):1458–1464Google Scholar
  3. Baluchnejadmojarad T, Eftekhari S-M, Jamali-Raeufy N, Haghani S, Zeinali H, Roghani M (2017) The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson’s disease: involvement of PKA/CaMKII/CREB signaling. Exp Gerontol 100:70–76Google Scholar
  4. Basak I, Patil KS, Alves G, Larsen JP, Møller SG (2016) microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. Cell Mol Life Sci 73(4):811–827Google Scholar
  5. Blaser H, Dostert C, Mak TW, Brenner D (2016) TNF and ROS crosstalk in inflammation. Trends Cell Biol 26(4):249–261Google Scholar
  6. Chen K, Rajewsky N (2007) The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8(2):93–103Google Scholar
  7. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Wang CY (2001) Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor–mediated transcription. J Cell Biol 152(1):87–96Google Scholar
  8. Chen C-D, Li H, Liang J, Hixson K, Zeldich E, Abraham CR (2015) The anti-aging and tumor suppressor protein klotho enhances differentiation of a human oligodendrocytic hybrid cell line. J Mol Neurosci 55(1):76–90Google Scholar
  9. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, Messing RO (2006) PKCε increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci 103(21):8215–8220Google Scholar
  10. D’amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F et al (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol 45(3):202–207Google Scholar
  11. Davanso MR, Caliari-Oliveira C, Couri CEB, Covas DT, de Oliveira Leal AM, Voltarelli JC et al (2019) DPP-4 inhibition leads to decreased pancreatic inflammatory profile and increased frequency of regulatory T cells in experimental type 1 diabetes. Inflammation.:1–14Google Scholar
  12. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius A (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-κB activity: a role for p50. Clin Exp Immunol 135(1):64–73Google Scholar
  13. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696–1705Google Scholar
  14. Du Q, Geller DA (2010) Cross-regulation between Wnt and NF-kappaB signaling pathways. Immunopathol Dis Therap 1(3):155–181Google Scholar
  15. Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, Atasoy İL, Alaylıoğlu M, Araz ÖS, Önal B, Gündüz A, Apaydın H, Kızıltan G, Ulutin T, Gürvit H, Yılmazer S (2015) The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer’s disease, mild cognitive impairment or Parkinson’s disease. J Neuroimmunol 283:50–57Google Scholar
  16. German DC, Khobahy I, Pastor J, Kuro-o M, Liu X (2012) Nuclear localization of klotho in brain: an antiaging protein. Neurobiol Aging 33(7):1483. e25–1483. e30Google Scholar
  17. Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281(32):22429–22433Google Scholar
  18. Grigoropoulou P, Eleftheriadou I, Zoupas C, Diamanti-Kandarakis E, Tentolouris N (2013) Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance. Curr Diabetes Rev 9(5):412–417Google Scholar
  19. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN et al (2008) Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci 105(17):6415–6420Google Scholar
  20. Hirakawa H, Zempo H, Ogawa M, Watanabe R, Suzuki J-i, Akazawa H et al (2015) A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PLoS One 10(3):e0119360Google Scholar
  21. Idda ML, Munk R, Abdelmohsen K, Gorospe M (2018) Noncoding RNAs in Alzheimer’s disease. Wiley Interdiscip Rev 9(2):e1463Google Scholar
  22. Inestrosa NC, Toledo EM (2008) The role of Wnt signaling in neuronal dysfunction in Alzheimer’s disease. Mol Neurodegener 3(1):9Google Scholar
  23. Kokkinaki M, Abu-Asab M, Gunawardena N, Ahern G, Javidnia M, Young J, Golestaneh N (2013) Klotho regulates retinal pigment epithelial functions and protects against oxidative stress. J Neurosci 33(41):16346–16359Google Scholar
  24. Kornelius E, Lin CL, Chang HH, Li HH, Huang WN, Yang YS, Lu YL, Peng CH, Huang CN (2015) DPP-4 inhibitor linagliptin attenuates Aβ-induced cytotoxicity through activation of AMPK in neuronal cells. CNS Neurosci Ther 21(7):549–557Google Scholar
  25. Kuang X, Chen YS, Wang LF, Li YJ, Liu K, Zhang MX, Li LJ, Chen C, He Q, Wang Y, du JR (2014) Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer’s disease mouse model. Neurobiol Aging 35(1):169–178Google Scholar
  26. Leuner K, Schulz K, Schütt T, Pantel J, Prvulovic D, Rhein V, Müller WE (2012) Peripheral mitochondrial dysfunction in Alzheimer’s disease: focus on lymphocytes. Mol Neurobiol 46(1):194–204Google Scholar
  27. Liu L, Chan C (2014) The role of inflammasome in Alzheimer’s disease. Ageing Res Rev 15:6–15Google Scholar
  28. Massó A, Sánchez A, Gimenez-Llort L, Lizcano JM, Cañete M, García B, Torres-Lista V, Puig M, Bosch A, Chillon M (2015) Secreted and transmembrane α klotho isoforms have different spatio-temporal profiles in the brain during aging and Alzheimer’s disease progression. PLoS One 10(11):e0143623Google Scholar
  29. Müller M, Jäkel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM (2016) MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid. Mol Neurobiol 53(5):2894–2899Google Scholar
  30. Mytych J, Romerowicz-Misielak M, Koziorowski M (2018) Klotho protects human monocytes from LPS-induced immune impairment associated with immunosenescent-like phenotype. Mol Cell Endocrinol 470:1–13Google Scholar
  31. Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, Carson DA (2002) Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene. 21(43):6598–6605Google Scholar
  32. Silaidos C, Pilatus U, Grewal R, Matura S, Lienerth B, Pantel J, Eckert GP (2018) Sex-associated differences in mitochondrial function in human peripheral blood mononuclear cells (PBMCs) and brain. Biol Sex Differ 9(1):34Google Scholar
  33. Srivastava S, Tsongalis GJ, Kaur P (2016) Role of microRNAs in regulation of the TNF/TNFR gene superfamily in chronic lymphocytic leukemia. Clin Biochem 49(16–17):1307–1310Google Scholar
  34. Tan L, Yu J-T, Hu N, Tan L (2013) Non-coding RNAs in Alzheimer’s disease. Mol Neurobiol 47(1):382–393Google Scholar
  35. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1–25Google Scholar
  36. Tapia-Rojas C, Inestrosa NC (2018) Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer’s disease in J20-APP transgenic and wild-type mice. J Neurochem 144:443–465Google Scholar
  37. Yamadera S, Nakamura Y, Inagaki M, Kenmotsu S, Nohara T, Sato N, Gotoh H (2018) Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes. Inflammation and Regeneration 38(1):13Google Scholar
  38. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M (2005) Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 280(45):38029–38034Google Scholar
  39. Zeldich E, Chen C-D, Colvin TA, Bove-Fenderson EA, Liang J, Zhou TBT et al (2014) The neuroprotective effect of klotho is mediated via regulation of members of the redox system. J Biol Chem 289(35):24700–24715Google Scholar
  40. Zhao Y, Yang F, Li W, Xu C, Li L, Chen L, Liu Y, Sun P (2017) miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. Tumor Biol 39(2):1010428317692264Google Scholar
  41. Zhou Y, Kuang Y, Zhou J (2017) Klotho protects against LPS-induced inflammation injury by inhibiting Wnt and NF-κB pathways in HK-2 cells. Pharmazie 72(4):227–231Google Scholar
  42. Zhu H-C, Wang L-M, Wang M, Song B, Tan S, Teng J-F, Duan DX (2012) MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1. Brain Res Bull 88(6):596–601Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neuroscience, Faculty of Advanced Technologies in MedicineIran University of Medical SciencesTehranIran
  2. 2.Department of Physiology, School of MedicineIran University of Medical SciencesTehranIran
  3. 3.Department of Biochemistry, School of MedicineIran University of Medical SciencesTehranIran
  4. 4.Department of Clinical Biochemistry, Faculty of MedicineKurdistan University of Medical SciencesSanandajIran
  5. 5.Neurophysiology Research CenterShahed UniversityTehranIran
  6. 6.Department of NeurologySchool of Medicine, Shahed UniversityTehranIran

Personalised recommendations